Anti-Human CD20 (Rituximab) – PE
Anti-Human CD20 (Rituximab) – PE
Product No.: LT904
- -
- -
Product No.LT904 Clone 10F381 Target CD20 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names B1; S7; Bp35; CVID5; MS4A2; LEU-16; MS4A1; membrane spanning 4-domains A1 Isotype Human IgG1κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human/Rhesus Monkey/Cynomolgus Monkey Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human lymphoblastoid cell line SB. Product Concentration 0.2 mg/ml Formulation This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm) RRIDAB_2894034 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Rituximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only. Antigen Distribution CD20 is primarily found on the surface of immune system B cells. CD20 is highly expressed in the lymph node, and to a lesser extent, the spleen and appendix. Background CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects. Antigen DetailsPubMed NCBI Gene Bank ID UniProt.org Research Area Costimulatory Molecules . Immunology References & Citations1. Mato, A. et al. (2018) Oncologist. 23(3):288-296. 2. Richards, K. et al. (2018) Front Oncol. 8: 163. Technical Protocols |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT900 | |
LT904 | |
LT903 | |
LT911 | |
LT905 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
